

Efficacy and Tolerability of Prostaglandin Analogs

Journal of Glaucoma

17, 667-673

DOI: [10.1097/ijg.0b013e3181666557](https://doi.org/10.1097/ijg.0b013e3181666557)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pharmacotherapy of intraocular pressure “ part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opinion on Pharmacotherapy, 2009, 10, 2859-2870.	1.8	47
2	Intraocular Pressure and Conjunctival Hyperaemia with Bimatoprost Every 48 Hours Versus Every 24 Hours. Journal of Optometry, 2009, 2, 134-137.	1.3	0
4	Influence of Signal Strength on OCT Measurements. Journal of Glaucoma, 2009, 18, 499-500.	1.6	4
7	Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects. Japanese Journal of Ophthalmology, 2010, 54, 286-290.	1.9	15
8	Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clinical Ophthalmology, 2010, 4, 741.	1.8	48
9	Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension. Clinical Ophthalmology, 2010, 4, 877.	1.8	5
10	A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost. Clinical Ophthalmology, 2010, 4, 1433.	1.8	13
11	Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension. American Journal of Ophthalmology, 2010, 149, 661-671.e1.	3.3	76
12	Comparison of Travoprost and Bimatoprost plus Timolol Fixed Combinations in Open-Angle Glaucoma Patients Previously Treated with Latanoprost plus Timolol Fixed Combination. American Journal of Ophthalmology, 2010, 150, 575-580.	3.3	30
13	Hyperemia Reduction After Administration of a Fixed Combination of Bimatoprost and Timolol Maleate to Patients on Prostaglandin or Prostaglandin Monotherapy. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 611-615.	1.4	9
14	Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Experimental Eye Research, 2011, 93, 265-270.	2.6	46
15	Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Current Medical Research and Opinion, 2011, 27, 1949-1958.	1.9	29
16	Demonstration of an online tool to assist managed care formulary evidence-based decision making: meta-analysis of topical prostaglandin analog efficacy. Therapeutics and Clinical Risk Management, 2011, 7, 283.	2.0	3
18	Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. Statistics in Medicine, 2011, 30, 2511-2535.	1.6	38
19	Role of fixed combinations in the management of open-angle glaucoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 91-99.	1.4	14
20	Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure. BMJ Open, 2012, 2, e001106.	1.9	17
21	Efficacy and Tolerability of Prostaglandin-Timolol Fixed Combinations: A Meta-Analysis of Randomized Clinical Trials. European Journal of Ophthalmology, 2012, 22, 5-18.	1.3	62
22	Long-term Effect of BAK-free Travoprost on Ocular Surface and Intraocular Pressure in Glaucoma Patients After Transition From Latanoprost. Journal of Glaucoma, 2012, 21, 60-64.	1.6	37

#	ARTICLE	IF	CITATIONS
23	Long-term Medical Management of Primary Open-Angle Glaucoma and Ocular Hypertension in the UK. <i>Journal of Glaucoma</i> , 2012, 21, 433-449.	1.6	12
24	What Comparative Effectiveness Research Is Needed? A Framework for Using Guidelines and Systematic Reviews to Identify Evidence Gaps and Research Priorities. <i>Annals of Internal Medicine</i> , 2012, 156, 367.	3.9	61
25	A review of the use of latanoprost for glaucoma since its launch. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 723-745.	1.8	67
26	Drugs used in ocular treatment. <i>Side Effects of Drugs Annual</i> , 2012, 34, 761-768.	0.6	0
27	Quality of life of glaucoma patients under medical therapy with different prostaglandins. <i>Clinical Ophthalmology</i> , 2012, 6, 1749.	1.8	11
28	Initial Treatment: Prostaglandin Analog or Selective Laser Trabeculoplasty. <i>Journal of Current Glaucoma Practice</i> , 2012, 6, 99-103.	0.5	5
29	Cost-effectiveness comparison between non-penetrating deep sclerectomy and maximum-tolerated medical therapy for glaucoma within the Brazilian National Health System (SUS). <i>Arquivos Brasileiros De Oftalmologia</i> , 2012, 75, 11-15.	0.5	8
30	Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension. <i>Clinical Ophthalmology</i> , 2012, 6, 739.	1.8	15
31	An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial. <i>Clinical Ophthalmology</i> , 2012, 6, 2097.	1.8	12
33	Citation of Previous Meta-analyses on the Same Topic. <i>Ophthalmology</i> , 2013, 120, 1113-1119.	5.2	24
34	Effects of SofZia®-preserved travoprost and benzalkonium chloride®-preserved latanoprost on the ocular surface – a multicentre randomized single-masked study. <i>Acta Ophthalmologica</i> , 2013, 91, e7-e14.	1.1	44
35	Therapeutic uses of prostaglandin F ₂ analogues in ocular disease and novel synthetic strategies. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 104-105, 109-121.	1.9	27
36	A Novel Convergent Synthesis of the Antiglaucoma PGF ₂ Analogue Bimatoprost. <i>Chirality</i> , 2013, 25, 170-179.	2.6	11
38	Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. <i>British Journal of Ophthalmology</i> , 2013, 97, 989-993.	3.9	38
40	A Randomized, Prospective Study of Bimatoprost 0.01% or Travoprost/Timolol in Patients Previously Treated with Latanoprost and Timolol to Reduce Intraocular Pressure. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 876-881.	1.4	4
41	Comparative Effectiveness of Treatments for Open-Angle Glaucoma: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2013, 158, 271.	3.9	214
42	Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes. <i>Clinical Ophthalmology</i> , 2013, 7, 1549.	1.8	15
43	Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials. <i>Clinical Ophthalmology</i> , 2014, 8, 643.	1.8	16

#	ARTICLE	IF	CITATIONS
44	Latanoprost in the treatment of glaucoma. <i>Clinical Ophthalmology</i> , 2014, 8, 1967.	1.8	70
45	Managing adverse effects of glaucoma medications. <i>Clinical Ophthalmology</i> , 2014, 8, 903.	1.8	103
46	An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan® RC Early Analysis Review (CLEAR) trial. <i>Clinical Ophthalmology</i> , 2014, 8, 1031.	1.8	11
47	Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study. <i>Clinical Ophthalmology</i> , 2014, 8, 725.	1.8	4
48	Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma. <i>Korean Journal of Ophthalmology: KJO</i> , 2014, 28, 399.	1.1	21
49	Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. <i>Croatian Medical Journal</i> , 2014, 55, 468-480.	0.7	15
50	Activation of the Prostanoid FP Receptor Inhibits Adipogenesis Leading to Deepening of the Upper Eyelid Sulcus in Prostaglandin-Associated Periorbitopathy. , 2014, 55, 1269.		68
51	Effectiveness of Intraocular Pressure-Lowering Medication Determined by Washout. <i>JAMA Ophthalmology</i> , 2014, 132, 390.	2.5	23
52	Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting. <i>BMC Ophthalmology</i> , 2014, 14, 160.	1.4	8
53	Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma. <i>Journal of Glaucoma</i> , 2014, 23, 535-540.	1.6	23
54	Effects of Prostaglandin Analogues on Aqueous Humor Outflow Pathways. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014, 30, 102-109.	1.4	99
56	Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1585-1593.	1.9	44
57	Confocal Microscopy of Epithelial and Langerhans Cells of the Cornea in Patients Using Travoprost Drops Containing Two Different Preservatives. <i>Pathology and Oncology Research</i> , 2014, 20, 741-746.	1.9	23
58	Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China. <i>BMC Ophthalmology</i> , 2014, 14, 21.	1.4	9
59	Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog. <i>Ophthalmology and Eye Diseases</i> , 2014, 6, OED.S12445.	1.2	10
60	Relative Efficacy and Safety of Preservative-free Latanoprost (T2345) for the Treatment of Open-Angle Glaucoma and Ocular Hypertension. <i>Journal of Glaucoma</i> , 2014, 23, e69-e75.	1.6	31
61	Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study. <i>BMC Ophthalmology</i> , 2015, 15, 166.	1.4	21
62	The Measurement of Bulbar Hyperemia: Challenges and Pitfalls. <i>European Journal of Ophthalmology</i> , 2015, 25, 273-279.	1.3	20

#	ARTICLE	IF	CITATIONS
63	Unilateral Prostaglandin-Associated Periorbitopathy. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2015, 31, 373-378.	0.8	36
64	Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2617.	4.3	4
65	Twenty-four hour efficacy of glaucoma medications. <i>Progress in Brain Research</i> , 2015, 221, 297-318.	1.4	20
66	Polyquaternium-1âPreserved Travoprost 0.003% or Benzalkonium ChlorideâPreserved Travoprost 0.004% for Glaucoma and Ocular Hypertension. <i>American Journal of Ophthalmology</i> , 2015, 160, 266-274.e1.	3.3	27
67	Bimatoprost 0.01â% for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting. <i>Japanese Journal of Ophthalmology</i> , 2015, 59, 325-334.	1.9	5
68	A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension. <i>Clinical Ophthalmology</i> , 2016, 10, 635.	1.8	3
69	Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 1759-1765.	1.8	8
70	Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 2085-2091.	1.8	13
71	Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial. <i>International Journal of Clinical Practice</i> , 2016, 70, 577-586.	1.7	6
72	Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost. <i>Journal of Glaucoma</i> , 2016, 25, e610-e614.	1.6	14
73	Network Meta-analysis for Clinical Practice Guidelines: A Case Study on First-Line Medical Therapies for Primary Open-Angle Glaucoma. <i>Annals of Internal Medicine</i> , 2016, 164, 674.	3.9	33
74	Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1201-1208.	4.1	10
75	Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1279-1289.	3.3	71
76	Tolerability and efficacy of bimatoprost 0.01â% in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01â% (APPEAL Taiwan) study. <i>BMC Ophthalmology</i> , 2016, 16, 162.	1.4	4
77	Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. <i>American Journal of Ophthalmology</i> , 2016, 168, 250-259.	3.3	85
78	Effect of Switching From Latanoprost to Bimatoprost in Primary Open-Angle Glaucoma Patients Who Experienced Intraocular Pressure Elevation During Treatment. <i>Journal of Glaucoma</i> , 2016, 25, e359-e366.	1.6	5
79	Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 117-128.	2.4	7
80	24-h Efficacy of Glaucoma Treatment Options. <i>Advances in Therapy</i> , 2016, 33, 481-517.	2.9	35

#	ARTICLE	IF	CITATIONS
99	Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. British Journal of Pharmacology, 2019, 176, 1079-1089.	5.4	40
100	Comment on: Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase After Cataract Surgery in Eyes With Glaucoma. American Journal of Ophthalmology, 2020, 210, 192.	3.3	0
101	Reply to Comment on: Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase After Cataract Surgery in Eyes With Glaucoma. American Journal of Ophthalmology, 2020, 210, 192-193.	3.3	0
103	Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment. Journal of Ophthalmology, 2020, 2020, 1-14.	1.3	54
104	Orbital Fat Volume After Treatment with Topical Prostaglandin Agonists. , 2020, 61, 46.		1
105	Intraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials. American Journal of Ophthalmology, 2020, 216, 110-120.	3.3	10
106	Comparison of preserved bimatoprost 0.01% with preservative-free tafluprost: A randomised, investigator-masked, 3-month crossover, multicentre trial, SPORT II. European Journal of Ophthalmology, 2021, , 112067212110065.	1.3	1
107	Effect and Safety of Travoprost 0.003% in Open Angle Glaucoma. Journal of Korean Ophthalmological Society, 2021, 62, 531-537.	0.2	0
109	Evaluating the Relationship of Intraocular Pressure and Anterior Chamber Volume With Use of Prostaglandin Analogues. Journal of Glaucoma, 2021, 30, 421-427.	1.6	8
111	Prostaglandin analogues: past, present, and future. Ophthalmology Journal, 2017, 10, 40-52.	0.2	13
112	Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost. Open Ophthalmology Journal, 2016, 10, 94-102.	0.2	1
113	Drugs used in ocular treatment. Side Effects of Drugs Annual, 2011, , 977-988.	0.6	0
114	Clinical Experience in the Management of Primary Open Angle Glaucoma. Highlights of Ophthalmology, 2012, 40, 14-16.	0.0	0
115	Tolerancia y Efectividad de los Análogos de Prostaglandinas en Pacientes Glaucomatosos. Highlights of Ophthalmology, 2013, 41, 22-26.	0.0	0
116	Tolerance and Effectivity of Prostaglandin Analogues in Glaucoma Patients. Highlights of Ophthalmology, 2013, 41, 19-22.	0.0	0
117	Eye Medications and Its Effect on Orbital Fat and Cosmesis. , 2020, , 51-63.		0
119	Selective laser trabeculoplasty is safe and effective in patients previously treated with prostaglandin analogs: An evidence-based review. International Ophthalmology, 2023, 43, 677-695.	1.4	2
120	Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Frontiers in Pharmacology, 0, 13, .	3.5	10

#	ARTICLE	IF	CITATIONS
121	Cytotoxicity, Mitochondrial Functionality, and Redox Status of Human Conjunctival Cells after Short and Chronic Exposure to Preservative-Free Bimatoprost 0.03% and 0.01%: An In Vitro Comparative Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14113.	4.1	1
122	The Effect of Latanoprost on Choroidal Vascularity Index in Glaucoma and Ocular Hypertension. <i>Journal of Glaucoma</i> , 2022, 31, 972-978.	1.6	1
123	Pharmacotherapy of glaucoma in terms of evidence-based medicine. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2023, , 44-54.	0.5	0
124	The long-term effects of topical latanoprost 0.005% treatment on pupillary functions: A 2-year longitudinal study. <i>European Journal of Ophthalmology</i> , 0, , .	1.3	0